(Total Views: 509)
Posted On: 06/19/2021 10:05:41 PM
Post# of 30066
LAUREN CHUNG, PhD – DIRECTOR
https://todosmedical.com/about-us/board-of-advisors/
Partner
Lauren Chung, PhD
Founder | Minleigh LLC
https://korea.yozma.asia/partners/?lang=en
Dr. Lauren Chung to its Board of Directors
Aditxt
https://investorshangout.com/post/view?id=616...z6yGhUk8Yf
Lauren Chung, Ph.D
BOD - CURE Pharmaceutical
https://curepharmaceutical.com/about-us/board-of-directors/
TODOS
"The Company intends to utilize a portion of the proceeds from a recently completed $3.3 million fixed price crossover investment with Yozma Group, a venture capital firm from South Korea, to help with the Tollovid launch."
"... In addition to the Tollovid launch, the Company is utilizing the proceeds from these investments to retire certain outstanding debts, further advance the ongoing Phase 2 clinical trial of the Company’s oral 3CL protease targeting drug candidate Tollovir™ for hospitalized COVID-19 patients, the completion of initial clinical studies for the Company’s 3CL protease targeting COVID-19 diagnostic assay Tollotest™ and general corporate purposes."
https://investor.todosmedical.com/news-events...le-for-new
https://todosmedical.com/about-us/board-of-advisors/
Partner
Lauren Chung, PhD
Founder | Minleigh LLC
https://korea.yozma.asia/partners/?lang=en
Dr. Lauren Chung to its Board of Directors
Aditxt
https://investorshangout.com/post/view?id=616...z6yGhUk8Yf
Lauren Chung, Ph.D
BOD - CURE Pharmaceutical
https://curepharmaceutical.com/about-us/board-of-directors/
TODOS
"The Company intends to utilize a portion of the proceeds from a recently completed $3.3 million fixed price crossover investment with Yozma Group, a venture capital firm from South Korea, to help with the Tollovid launch."
"... In addition to the Tollovid launch, the Company is utilizing the proceeds from these investments to retire certain outstanding debts, further advance the ongoing Phase 2 clinical trial of the Company’s oral 3CL protease targeting drug candidate Tollovir™ for hospitalized COVID-19 patients, the completion of initial clinical studies for the Company’s 3CL protease targeting COVID-19 diagnostic assay Tollotest™ and general corporate purposes."
https://investor.todosmedical.com/news-events...le-for-new
(0)
(0)
